Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
Star Copper Expands Historical Copper System with Largest Drill Program in Project History with Pervasive Mineralization Across Multiple Intercepts
QIMC Further Derisks Nova Scotia Natural Hydrogen Multi-Gas System with New Thermogenic Gas and Helium Results
Flow Metals Secures Little Gold Creek Headwaters, Completing Strategic Consolidation of Sixtymile Gold District
